vs
Side-by-side financial comparison of GCL Global Holdings Ltd (GCL) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
GCL Global Holdings Ltd is the larger business by last-quarter revenue ($98.7M vs $66.0M, roughly 1.5× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -5.2%, a 44.6% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $-5.2M).
GCL Global Holdings Ltd is a leading clean energy enterprise focusing on R&D, production and operation of photovoltaic products, energy storage systems and low-carbon energy solutions. Its main markets cover Asia, Europe, North America, serving utility, commercial and residential distributed energy users across the globe.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
GCL vs SLNO — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $98.7M | $66.0M |
| Net Profit | $-5.1M | $26.0M |
| Gross Margin | 11.0% | 98.3% |
| Operating Margin | -6.7% | 33.5% |
| Net Margin | -5.2% | 39.4% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 134.0% |
| EPS (diluted) | $-0.04 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $98.7M | $66.0M | ||
| Q2 25 | $142.1M | $32.7M | ||
| Q3 24 | $36.1M | — |
| Q3 25 | $-5.1M | $26.0M | ||
| Q2 25 | $5.6M | $-4.7M | ||
| Q3 24 | $-1.9M | — |
| Q3 25 | 11.0% | 98.3% | ||
| Q2 25 | 15.0% | 97.9% | ||
| Q3 24 | 16.2% | — |
| Q3 25 | -6.7% | 33.5% | ||
| Q2 25 | 2.3% | -20.0% | ||
| Q3 24 | -5.6% | — |
| Q3 25 | -5.2% | 39.4% | ||
| Q2 25 | 3.9% | -14.4% | ||
| Q3 24 | -5.2% | — |
| Q3 25 | $-0.04 | $0.47 | ||
| Q2 25 | $0.05 | $-0.09 | ||
| Q3 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.6M | $498.9M |
| Total DebtLower is stronger | $52.0M | — |
| Stockholders' EquityBook value | $33.1M | $494.8M |
| Total Assets | $159.9M | $599.9M |
| Debt / EquityLower = less leverage | 1.57× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $16.6M | $498.9M | ||
| Q2 25 | $18.2M | $286.8M | ||
| Q3 24 | $2.7M | — |
| Q3 25 | $52.0M | — | ||
| Q2 25 | $11.9M | — | ||
| Q3 24 | — | — |
| Q3 25 | $33.1M | $494.8M | ||
| Q2 25 | $35.9M | $240.1M | ||
| Q3 24 | $15.9M | — |
| Q3 25 | $159.9M | $599.9M | ||
| Q2 25 | $101.6M | $332.3M | ||
| Q3 24 | $49.6M | — |
| Q3 25 | 1.57× | — | ||
| Q2 25 | 0.33× | — | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | $43.5M |
| Free Cash FlowOCF − Capex | $-5.2M | $43.5M |
| FCF MarginFCF / Revenue | -5.3% | 65.8% |
| Capex IntensityCapex / Revenue | 0.4% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-4.8M | $43.5M | ||
| Q2 25 | $-10.3M | $-12.6M | ||
| Q3 24 | $6.1M | — |
| Q3 25 | $-5.2M | $43.5M | ||
| Q2 25 | $-10.5M | $-12.6M | ||
| Q3 24 | — | — |
| Q3 25 | -5.3% | 65.8% | ||
| Q2 25 | -7.4% | -38.6% | ||
| Q3 24 | — | — |
| Q3 25 | 0.4% | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q3 24 | — | — |
| Q3 25 | — | 1.67× | ||
| Q2 25 | -1.84× | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
